Poolbeg Pharma

News

Jeremy Skillington, Poolbeg's chief executive

Poolbeg expects first data for CRS drug in the summer

A trial to see if Poolbeg's POLB-001 can prevent cytokine release syndrome in multiple myeloma treated with immunotherapy Tecvayli will start soon.

Oncology

Interview at ESMO 2025 with Liam Tremble

ESMO25: Transforming the cancer immunotherapy field, with Po...

Onsite at ESMO 2025 in Berlin, pharmaphorum spoke with Poolbeg's Liam Tremble about their work on CRS in relapsed/refractory multiple myeloma.

News

Poolbeg slumps as Hookipa merger is called off

A proposed merger of the UK's Poolbeg with Austrian biotech Hookipa has been called off after the latter abruptly withdrew from negotiations.

News

London-listed Poolbeg discussing Hookipa merger

The UK's Poolbeg Pharma has disclosed that it is in talks over a possible takeover by Hookipa, an Austrian biotech that is listed on the Nasdaq.

News

Poolbeg licences candidate for broad-spectrum respiratory in...

Poolbeg Pharma has licenced a candidate for nasal immunotherapy, developed by the University of Warwick, targeting respiratory infections, such as influenza and coronavirus.

Poolbeg expects first data for CRS drug in the summer

ESMO25: Transforming the cancer immunotherapy field, with Po...

Poolbeg slumps as Hookipa merger is called off

London-listed Poolbeg discussing Hookipa merger

Poolbeg licences candidate for broad-spectrum respiratory in...

NICE says Libtayo can be used for advanced cervical cancer

Discover a new era of healthcare panel engagement: Grounded ...

Poolbeg Pharma

Editor's Picks